Lonza sets new mid-term targets, confirms 2026 outlook

By Reuters News

Oct 14 (Reuters) - Swiss contract drug manufacturer Lonza LONN.S set new mid-term targets and confirmed its 2026 outlook on Wednesday ahead of its capital markets day, while saying third-quarter performance was in line with expectations across its business areas.

Lonza is seeking to become a pure-play drug manufacturer once it finalizes the planned sale of its Capsules & Health Ingredients business. Closing of the $3 billion deal, agreed with Lone Star Funds in March, is expected by the end of 2026.

  • Lonza continues to guide for a 2026 core EBITDA margin of 33% to 34%, having lifted the guidance in July

  • For the medium-term, it targets constant-currency organic sales growth of 10% to 13%, core EBITDA growth ahead of sales growth, and a core EBITDA margin in a high thirties percentage

  • "We are ready to double down on bolt-on acquisitions in line with the One Lonza strategy," Lonza said in a presentation

  • Lonza said its key biologics site in Vacaville could reach peak sales of up to 2 billion Swiss francs ($2.4 billion) in the early 2030s at constant exchange rates

  • CFO Philippe Deecke said in July that Vacaville sales would remain broadly flat through 2028, with more meaningful growth expected after that

($1 = 0.8317 Swiss francs)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.